Profile data is unavailable for this security.
About the company
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
- Revenue in EUR (TTM)6.81bn
- Net income in EUR151.80m
- Incorporated1987
- Employees23.74k
- LocationGrifols SAParque Empresarial Can Sant JoanAvinguda de la Generalitat, 152-158SANT CUGAT DEL VALLES 08174SpainESP
- Phone+34 935710000
- Fax+34 935710267
- Websitehttps://www.grifols.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corcept Therapeutics Incorporated | 600.08m | 135.39m | 5.59bn | 352.00 | 44.04 | 9.14 | 40.98 | 9.32 | 1.27 | 1.27 | 5.64 | 6.12 | 0.9121 | 1.26 | 13.32 | 1,785,668.00 | 20.58 | 21.17 | 25.10 | 23.85 | 98.44 | 98.52 | 22.56 | 27.23 | 3.64 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
| Beijing Tiantan Biological Products Corp | 690.13m | 168.08m | 5.75bn | 4.86k | 34.19 | 4.09 | -- | 8.33 | 0.6444 | 0.6444 | 2.65 | 5.38 | 0.3471 | 0.8137 | 198.92 | 1,076,946.00 | 11.47 | 11.71 | 16.75 | 16.50 | 54.23 | 49.39 | 33.05 | 27.71 | 3.31 | -- | 0.0046 | 16.67 | 21.57 | 12.06 | 25.99 | 16.85 | 29.67 | 38.97 |
| Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd | 10.08bn | 451.58m | 5.85bn | 28.05k | 13.74 | 1.30 | -- | 0.5808 | 2.11 | 2.11 | 46.99 | 22.28 | 0.9946 | 6.07 | 4.60 | 2,723,576.00 | 4.71 | 5.90 | 8.93 | 12.40 | 16.55 | 18.70 | 4.74 | 5.56 | 1.15 | -- | 0.317 | 30.02 | 6.68 | 12.32 | 2.25 | 3.34 | 27.75 | 12.05 |
| Financiere de Tubize SA | 0.00 | 183.85m | 5.87bn | -- | 31.91 | 3.10 | 31.91 | -- | 4.13 | 4.13 | 0.00 | 42.45 | 0.00 | -- | -- | -- | 9.64 | 7.04 | 9.85 | 7.24 | -- | -- | -- | 145.70 | -- | -- | 0.0161 | 20.94 | -- | -- | 3.50 | -20.93 | -- | 11.61 |
| Orion Oyj | 1.43bn | 331.80m | 6.26bn | 3.82k | 18.83 | 6.75 | 15.99 | 4.38 | 2.36 | 2.36 | 10.16 | 6.58 | 0.9593 | 1.53 | 6.94 | 393,502.20 | 22.25 | 19.47 | 28.25 | 24.16 | 59.89 | 59.38 | 23.19 | 20.71 | 1.41 | 143.69 | 0.2174 | 91.83 | -11.26 | 4.01 | -37.97 | 1.89 | 11.82 | 1.55 |
| Elanco Animal Health Inc | 4.25bn | 195.71m | 6.32bn | 9.30k | 32.79 | 1.02 | 7.58 | 1.49 | 0.4087 | 0.4087 | 8.99 | 13.20 | 0.3224 | 1.21 | 5.09 | 478,924.70 | 1.48 | -3.27 | 1.64 | -3.65 | 54.69 | 54.28 | 4.60 | -11.53 | 1.31 | 0.9883 | 0.4005 | -- | 0.136 | 7.57 | -1,478.21 | -- | 2.74 | -- |
| Grifols SA | 6.81bn | 151.80m | 6.50bn | 23.74k | 47.00 | 1.26 | 9.95 | 0.9549 | 0.2213 | 0.2213 | 9.79 | 8.23 | 0.3115 | 1.21 | 9.02 | 286,836.40 | 1.00 | 2.39 | 1.34 | 3.05 | 38.51 | 40.26 | 3.21 | 7.54 | 0.8005 | 1.58 | 0.5620 | -- | 8.71 | 8.00 | -71.52 | -36.98 | -0.8127 | -- |
| Abbott India Ltd | 685.36m | 145.14m | 6.51bn | 3.81k | 44.85 | 16.36 | 42.47 | 9.50 | 604.57 | 604.57 | 2,854.72 | 1,657.05 | 1.27 | 5.32 | 15.71 | 15,904,690.00 | 26.82 | 20.92 | 36.97 | 28.59 | 45.09 | 44.20 | 21.18 | 17.26 | 1.71 | 131.36 | 0.0169 | 77.06 | 9.35 | 9.72 | 26.52 | 21.68 | 31.08 | 52.32 |
| Jazz Pharmaceuticals PLC | 3.81bn | 442.18m | 7.22bn | 2.80k | 17.62 | 1.81 | 6.78 | 1.89 | 7.10 | 7.10 | 60.27 | 69.01 | 0.3404 | 0.7371 | 5.91 | 1,425,969.00 | 3.97 | 1.48 | 4.46 | 1.62 | 89.37 | 88.79 | 11.65 | 4.26 | 3.74 | 2.82 | 0.5944 | 0.00 | 4.78 | 15.19 | 285.14 | -1.49 | -20.04 | -- |
| Beijing Tongrentang Co Ltd | 2.37bn | 214.78m | 7.40bn | 16.78k | 34.45 | 4.32 | -- | 3.12 | 1.19 | 1.19 | 13.09 | 9.46 | 0.5912 | 1.08 | 11.14 | 1,070,467.00 | 7.88 | 8.20 | 15.63 | 16.17 | 44.48 | 46.59 | 13.33 | 13.33 | 1.58 | -- | 0.1765 | 30.93 | 16.19 | 4.68 | 16.92 | 8.03 | -12.01 | 13.97 |
| Holder | Shares | % Held |
|---|---|---|
| Capital International Ltd.as of 07 Nov 2024 | 17.34m | 4.07% |
| DWS Investment GmbHas of 10 Jun 2024 | 13.78m | 3.23% |
| Capital Research & Management Co. (World Investors)as of 18 Sep 2024 | 13.57m | 3.19% |
| Flat Footed LLCas of 13 Aug 2024 | 13.34m | 3.13% |
| Hardman Johnston Global Advisors LLCas of 30 Sep 2024 | 13.19m | 3.10% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 9.13m | 2.14% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 9.02m | 2.12% |
| Mason Capital Management LLCas of 18 Sep 2024 | 9.01m | 2.11% |
| BNP Paribas Asset Management Europe SASas of 13 Mar 2024 | 8.38m | 1.97% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 7.14m | 1.68% |
